Priming B cell-mediated anti-HIV envelope responses by vaccination allows for the long-term control of infection in macaques exposed to a R5-tropic SHIV
- PMID: 15003872
- DOI: 10.1016/j.virol.2003.12.003
Priming B cell-mediated anti-HIV envelope responses by vaccination allows for the long-term control of infection in macaques exposed to a R5-tropic SHIV
Erratum in
- Virology. 2004 Jul 20;325(1):164
Abstract
The potential of vaccine-elicited anti-HIV envelope antibodies to control HIV-infection was evaluated by immunizing macaques with the HIV envelope protein and transiently depleting them of their CD8+ cells before intravenous challenge with the pathogenic CCR5-tropic SIV/HIV chimeric virus, SHIV(SF162P4). Although sterilizing immunity was not achieved, all vaccinated animals effectively controlled infection and remained free of disease for the duration of observation (over 3 years). In contrast, during the same period, the control animals progressed to disease. Both the vaccinees and the controls developed robust cell-mediated antiviral and neutralizing antibody responses following infection. A comparative analysis of these responses suggests that the more effective long-term control of infection by the vaccinated animals is due to the more rapid development of anti-HIV envelope antibodies. These studies suggest that priming by vaccination of B cell anti-HIV envelope responses maybe crucial for the long-term control of HIV infection.
Similar articles
-
Multi-envelope HIV-1 vaccine devoid of SIV components controls disease in macaques challenged with heterologous pathogenic SHIV.Vaccine. 2005 Nov 16;23(46-47):5306-20. doi: 10.1016/j.vaccine.2005.07.008. Epub 2005 Jul 20. Vaccine. 2005. PMID: 16095768
-
Protection of macaques against a SHIV with a homologous HIV-1 Env and a pathogenic SHIV-89.6P with a heterologous Env by vaccination with multiple gene-deleted SHIVs.Virology. 1999 Dec 20;265(2):252-63. doi: 10.1006/viro.1999.0049. Virology. 1999. PMID: 10600597
-
Viral evolution in macaques coinfected with CCR5- and CXCR4-tropic SHIVs in the presence or absence of vaccine-elicited anti-CCR5 SHIV neutralizing antibodies.Virology. 2006 Nov 25;355(2):138-51. doi: 10.1016/j.virol.2006.07.026. Epub 2006 Aug 22. Virology. 2006. PMID: 16920175
-
Humoral immunity to HIV, SIV, and SHIV.AIDS. 1998;12 Suppl A:S121-32. AIDS. 1998. PMID: 9632993 Review. No abstract available.
-
B-cell antigenic sites in the envelope proteins of primate lentiviruses and their role in vaccine development.AIDS. 1993;7 Suppl 1:S127-33. AIDS. 1993. PMID: 8395859 Review. No abstract available.
Cited by
-
Macaques infected with a CCR5-tropic simian/human immunodeficiency virus (SHIV) develop broadly reactive anti-HIV neutralizing antibodies.J Virol. 2007 Jun;81(12):6402-11. doi: 10.1128/JVI.00424-07. Epub 2007 Mar 28. J Virol. 2007. PMID: 17392364 Free PMC article.
-
Rhesus macaque polyclonal and monoclonal antibodies inhibit simian immunodeficiency virus in the presence of human or autologous rhesus effector cells.J Virol. 2006 Sep;80(18):9217-25. doi: 10.1128/JVI.02746-05. J Virol. 2006. PMID: 16940533 Free PMC article.
-
Efficient protein boosting after plasmid DNA or recombinant adenovirus immunization with HIV-1 vaccine constructs.Vaccine. 2007 Feb 9;25(8):1398-408. doi: 10.1016/j.vaccine.2006.10.046. Epub 2006 Nov 7. Vaccine. 2007. PMID: 17113201 Free PMC article.
-
Differential pathogenicity of SHIV infection in pig-tailed and rhesus macaques.J Med Primatol. 2008 Dec;37 Suppl 2(Suppl 2):13-23. doi: 10.1111/j.1600-0684.2008.00325.x. J Med Primatol. 2008. PMID: 19187427 Free PMC article.
-
HIV-1 CD4-induced (CD4i) gp120 epitope vaccines promote B and T-cell responses that contribute to reduced viral loads in rhesus macaques.Virology. 2014 Dec;471-473:81-92. doi: 10.1016/j.virol.2014.10.001. Epub 2014 Oct 28. Virology. 2014. PMID: 25461534 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
